Phoenix Holdings Ltd. boosted its position in shares of Zoetis Inc (NYSE:ZTS) by 27.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,346 shares of the company’s stock after purchasing an additional 2,218 shares during the quarter. Phoenix Holdings Ltd.’s holdings in Zoetis were worth $1,292,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in the company. Prospera Financial Services Inc increased its stake in shares of Zoetis by 15.7% in the second quarter. Prospera Financial Services Inc now owns 3,887 shares of the company’s stock worth $533,000 after purchasing an additional 528 shares in the last quarter. Meitav Dash Investments Ltd. grew its stake in shares of Zoetis by 88.5% during the second quarter. Meitav Dash Investments Ltd. now owns 123,953 shares of the company’s stock worth $16,987,000 after purchasing an additional 58,200 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its stake in shares of Zoetis by 19.6% during the second quarter. Sound View Wealth Advisors Group LLC now owns 3,983 shares of the company’s stock worth $546,000 after purchasing an additional 654 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Zoetis by 0.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 663,732 shares of the company’s stock worth $90,958,000 after purchasing an additional 3,610 shares in the last quarter. Finally, Coastline Trust Co grew its stake in shares of Zoetis by 9.1% during the second quarter. Coastline Trust Co now owns 25,755 shares of the company’s stock worth $3,529,000 after purchasing an additional 2,140 shares in the last quarter. Institutional investors own 91.42% of the company’s stock.
ZTS has been the subject of a number of analyst reports. UBS Group lowered their target price on shares of Zoetis from $146.00 to $126.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. G.Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Truist Financial boosted their target price on shares of Zoetis from $112.00 to $160.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. They noted that the move was a valuation call. Morgan Stanley upped their target price on shares of Zoetis from $125.00 to $167.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Stifel Nicolaus raised their target price on shares of Zoetis from $155.00 to $170.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Ten investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $151.50.
Shares of Zoetis stock traded down $0.20 during midday trading on Thursday, hitting $158.38. The company had a trading volume of 24,596 shares, compared to its average volume of 1,537,166. The company has a debt-to-equity ratio of 2.46, a quick ratio of 2.60 and a current ratio of 3.47. The stock has a market capitalization of $76.10 billion, a P/E ratio of 47.07, a P/E/G ratio of 4.59 and a beta of 0.80. The company has a 50 day moving average of $147.28 and a 200 day moving average of $134.50. Zoetis Inc has a 52-week low of $90.14 and a 52-week high of $163.98.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.25. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the prior year, the business posted $0.90 EPS. The firm’s quarterly revenue was up .1% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc will post 3.61 EPS for the current year.
In other Zoetis news, CEO Kristin C. Peck sold 10,500 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $131.31, for a total transaction of $1,378,755.00. Following the sale, the chief executive officer now directly owns 43,759 shares in the company, valued at approximately $5,745,994.29. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $137.29, for a total value of $161,864.91. Following the sale, the executive vice president now owns 17,514 shares in the company, valued at $2,404,497.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,922 shares of company stock worth $4,248,547. Company insiders own 0.17% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: When can a hold rating present a buying opportunity?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.